February 19, 2024Open Access

Immune-related serious adverse events with immune checkpoint inhibitors: Systematic review and network meta-analysis

COClara OliveiraUniversidade Estadual de Montes Claros BMBeatrice MainoliInstituto Português de Oncologia Francisco Gentil GDGonçalo S. DuarteUniversity of Lisbon

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Each ICI showed a unique safety profile, with certain events more frequently observed with specific ICIs, which should be considered when managing cancer patients.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Oliveira et al. (Mon,) studied this question.

synapsesocial.com/papers/69d7d5dca2a48916bbbee08f https://doi.org/https://doi.org/10.1007/s00228-024-03647-z

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.2009 · 45,129 citations
2Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review2017 · 924 citations
3GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables2011 · 10,562 citations
4Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group2017 · 1,994 citations
5Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations2018 · 1,352 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo